NCT03783936View on ClinicalTrials.gov

Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

January 24, 2019

Primary Completion Date

September 11, 2020

Study Completion Date

August 30, 2022

Conditions
Gastric AdenocarcinomaEsophageal AdenocarcinomaMetastasisHER-2 Gene Amplification
Interventions
DRUG

Oxaliplatin

Oxaliplatin 85 mg/m2

DRUG

Leucovorin

Leucovorin 400 mg/m2

DRUG

5 fluorouracil

5 fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion

DRUG

Trastuzumab

Trastuzumab 6 mg/kg loading dose C1D1 then 4 mg/kg Day 1

DRUG

Avelumab

Avelumab 800 mg

Trial Locations (7)

14263

Roswell Park Cancer Institute, Buffalo

27599

University of North Carolina at Chapel Hill, Chapel Hill

30322

Winship Cancer Insititute of Emory University, Atlanta

52242

University of Iowa Hospital and Clinics, Iowa City

60611

Northwestern University Feinberg School of Medicine, Chicago

91010

City of Hope, Duarte

07960

Atlantic Health System, Morristown

Sponsors

Collaborators (1)

EMD Serono
All Listed Sponsors
collaborator

EMD Serono

INDUSTRY

collaborator

University of North Carolina, Chapel Hill

OTHER

lead

Ashwin Somasundaram

OTHER

NCT03783936 - Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas | Biotech Hunter | Biotech Hunter